St. Jude Medical Announces Key Findings at ACC.12 - the 61st Annual Scientific Session and Expo of the American College of Cardiology
ST. PAUL, Minn.--(BUSINESS WIRE)--Mar 23, 2012-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced key clinical findings that will be presented at ACC.12, the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC), taking place March 24 to March 27 in Chicago at the McCormick Place Convention Center.
The new data will be presented via three posters that will be on display at ACC.12. Two studies reveal that the St. Jude Medical quadripolar pacing system can improve hemodynamic function and reduce inefficiencies of the heart. A third poster showcases a registry that investigated factors associated with fluoroscopy and radiation time during cardiac resynchronization therapy (CRT) procedures.
-- Benefits of Quadripolar Pacing Quadripolar pacing technology, available exclusively from St. Jude Medical with the Quartet(R) lead, allows physicians the ability to use multisite left-ventricular (LV) pacing. The two posters below examined the role of multisite pacing in improving hemodynamics and reducing dyssynchrony (a lack of synchronization in the chambers of the heart that may lead to inefficient pumping) as compared to traditional bi-ventricular pacing.
Acute hemodynamic benefits of multisite left ventricular pacing in CRT recipients - This study found that in 13 patients receiving a CRT implant, all 13 patients demonstrated hemodynamic improvement as a result of multisite pacing configuration options.* Multisite left ventricular pacing and acute mechanical dyssynchrony in heart failure patients -This study found that in 33 patients receiving a CRT implant, multisite pacing can reduce mechanical dyssynchrony beyond conventional bi-ventricular pacing, and may improve clinical response to CRT.* -- Factors affecting radiation exposure during CRT implantation: results of the LAND-IT registry - The LAND-IT registry was a prospective, multicenter registry of patients undergoing CRT implants for standard indications. In the registry, fluoroscopy time was collected at implant, along with other relevant anatomical, demographic and procedural data. Analysis of this registry found that in real world practice, there are large variations in total fluoroscopy time for CRT implants. Increase in fluoroscopy time was not associated with baseline patient demographic characteristics, but rather the occurrence of a high capture threshold, phrenic nerve stimulation or complex cardiac anatomy. New CRT tools and strategies may help to reduce fluoroscopy time during CRT implants.
For additional data and background on these studies, moderated poster presentations will take place on Monday, March 26 in McCormick Place South Hall A at the following times: -- Presentation 1221-369: Multisite left ventricular pacing improves acute mechanical dyssynchrony in heart failure patients - 9:30 - 10:30 a.m. CDT -- Presentation 1213-71: Acute hemodynamic benefits of multisite left ventricular pacing in CRT recipients - 11 a.m. - 12 p.m. CDT -- Presentation 1242-438: Factors affecting radiation exposure during CRT implantation: results of the LAND-IT registry - 11 a.m. - 12 p.m. CDT At ACC.12, St. Jude Medical will also host the Third Annual Optical Coherence Tomography (OCT) Symposium in Association with Massachusetts General Hospital. The Symposium will take place on Sunday, March 25 from 5:30 to 7:30 a.m. CDT. Advance registration is not required; however, the event is first come, first served and seating is limited.
The OCT Symposium will take place in Salon E on the fifth floor of the Chicago Marriott Magnificent Mile located at 540 North Michigan Avenue. Additional posters and clinical case presentations on OCT will also be available at ACC.12.
ACC.12 attendees can also visit St. Jude Medical at booth ?3013 at the McCormick Place Convention Center.
St. Jude Medical is proud to partner with physicians across the entire cardiovascular service line by offering products and technologies across cardiac specialties. ACC.12 provides an opportunity for society members to interact with the company's first-to-market technologies such as the Unify Quadra(R) CRT-D Quadripolar System and Quartet(R) pacing lead, ILUMIEN(TM) PCI Optimization System and the Safire(TM) BLU(TM) Duo irrigated ablation catheter.
*The CRT-D devices used in these studies are CE mark approved in Europe. Caution: Investigational Device. Limited by Federal (or United States) law to investigational use only.
About the American College of Cardiology The American College of Cardiology is transforming cardiovascular care and improving heart health through continuous quality improvement, patient-centered care, payment innovation and professionalism. The College is a 40,000-member nonprofit medical society comprised of physicians, surgeons, nurses, physician assistants, pharmacists and practice managers, and bestows credentials upon cardiovascular specialists who meet its stringent qualifications. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The ACC provides professional education and operates national registries for the measurement and improvement of quality care. More information about the association is available online at www.cardiosource.org/ACC.
About St. Jude Medical St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.
Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
CONTACT: St. Jude Medical, Inc.
J.C. Weigelt Investor Relations 651-756-4347 firstname.lastname@example.org or Kristi Warner Media Relations 651-756-2085 email@example.com KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS MINNESOTA INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY CARDIOLOGY HOSPITALS MEDICAL DEVICES OTHER HEALTH MANUFACTURING ENGINEERING GENERAL HEALTH SOURCE: St. Jude Medical, Inc.
Copyright Business Wire 2012 PUB: 03/23/2012 04:00 PM/DISC: 03/23/2012 04:00 PM http://www.businesswire.com/news/home/20120323005931/